<?xml version='1.0' encoding='utf-8'?>
<regulation prefix="Regulation" num=".02" citation="COMAR 10.34.42.02" title_num="10" subtitle_num="34" chapter_num="42" heading="Definitions.">
  <paragraph num="A.">
    <text>In this chapter, the following terms have the meanings indicated.</text>
  </paragraph>
  <paragraph num="B.">
    <text>Terms Defined.</text>
    <paragraph num="(1)">
      <text>“Board” means the Maryland Board of Pharmacy.</text>
    </paragraph>
    <paragraph num="(2)">
      <text>“Nicotine replacement therapy medication” means a nicotine-based treatment, including inhalers, gums, lozenges, nasal sprays, and patches, approved by the United States Food and Drug Administration that assists an individual to cease the use of products that contain nicotine.</text>
    </paragraph>
    <paragraph num="(3)">
      <text>“Primary care practitioner” means a licensed health care practitioner who:</text>
      <paragraph num="(a)">
        <text>Provides an individual’s primary care services; and</text>
      </paragraph>
      <paragraph num="(b)">
        <text>Is the primary coordinator of health care services for the individual.</text>
      </paragraph>
    </paragraph>
    <paragraph num="(4)">
      <text>“Visit summary” means:</text>
      <paragraph num="(a)">
        <text>A written record of the nicotine replacement therapy medication dispensed;</text>
      </paragraph>
      <paragraph num="(b)">
        <text>The name and contact information for the prescribing pharmacist; and</text>
      </paragraph>
      <paragraph num="(c)">
        <text>The information on the importance of regular appointments with the individual’s primary care practitioner.</text>
      </paragraph>
    </paragraph>
  </paragraph>
</regulation>